儿童慢性免疫性血小板减少症首选二线治疗的前瞻性评估:脾切除或免疫调节
该研究基于法国OBS'CEREVANCE和VIGICAIRE前瞻性队列,纳入137例以脾切除、羟氯喹、硫唑嘌呤或利妥昔单抗作为首选二线治疗的儿童慢性免疫性血小板减少症患者,比较各组24个月无事件生存率。结果显示脾切除组24个月无事件生存率最高(85%,95%CI 77;95),其次为利妥昔单抗(60%)、硫唑嘌呤(46%)和羟氯喹(37%),组间差异显著(log-rank P<.0001)。
要点
- 脾切除作为首选二线治疗,24个月无事件生存率为85%(95%CI 77;95)。
- 利妥昔单抗、硫唑嘌呤和羟氯喹的24个月无事件生存率分别为60%、46%和37%。
- 女性青少年伴抗核抗体阳性者可能从羟氯喹治疗中获益。
核心结论
- 在儿童慢性免疫性血小板减少症中,脾切除作为首选二线治疗与24个月时更好的应答相关。
研究设计与样本
- 基于法国OBS'CEREVANCE和VIGICAIRE前瞻性队列,纳入137例以脾切除、羟氯喹、硫唑嘌呤或利妥昔单抗作为首选二线治疗的儿童慢性免疫性血小板减少症患者,治疗时间为1989年至2016年。
主要发现
- 全队列24个月无事件生存率为62%(95%CI 55;71)。
- 脾切除组56例,24个月无事件生存率为85%(95%CI 77;95)。
- 利妥昔单抗组23例,24个月无事件生存率为60%(95%CI 44;84)。
- 硫唑嘌呤组24例,24个月无事件生存率为46%(95%CI 30;71)。
- 羟氯喹组34例,24个月无事件生存率为37%(95%CI 24;59),组间log-rank P<.0001。
关键数值与推荐
- 脾切除组中,脾切除时年龄大于10岁倾向于改善无事件生存(P=.05)。
- 女性青少年伴抗核抗体阳性者从羟氯喹治疗中获益。
临床怎么用
- 对于儿童慢性免疫性血小板减少症的首选二线治疗,脾切除在24个月无事件生存方面表现优于利妥昔单抗、硫唑嘌呤和羟氯喹。
- 对于女性青少年伴抗核抗体阳性的患者,可考虑羟氯喹作为治疗选择。
局限性
- 研究为前瞻性队列设计,非随机对照,不同治疗组间可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To describe 4 subgroups of pediatric patients treated with splenectomy, hydroxychloroquine, azathioprine, or rituximab as the first-option, second-line treatment for chronic immune thrombocytopenia. STUDY DESIGN: Selection of patients with chronic immune thrombocytopenia from the French national prospective cohort of pediatric autoimmune cytopenia OBS'CEREVANCE and VIGICAIRE study, treated by splenectomy, hydroxychloroquine, azathioprine, or rituximab as a first second-line treatment. RESULTS: For 137 patients, treated between 1989 and 2016, the median follow-up after diagnosis and after treatment initiation was 8.5 (2.8-26.4) years and 4.7 (1.1-25.1) years, respectively. Median age at diagnosis and at initiation of treatment were 9 (0.7; 16) and 12 (2; 18.1) years, respectively without significant difference between subgroups. For the whole cohort, 24-month event-free survival was 62% (95% CI 55; 71). It was 85% (95% CI 77; 95) for the 56 patients treated with splenectomy, 60% (95% CI 44; 84) for the 23 patients treated with rituximab, 46% (95% CI 30; 71) for the 24 patients treated with azathioprine, and 37% (95% CI 24; 59) for the 34 patients treated with hydroxychloroquine (log-rank P < .0001). For the splenectomy subgroup, being older than 10 years at splenectomy tended to improve event-free survival (P = .05). Female teenagers with antinuclear antibody positivity benefited from hydroxychloroquine therapy. CONCLUSIONS: This national study, limiting pitfalls in the analysis of the effects of second-line therapies, showed that splenectomy remains the treatment associated with the better response at 24 months.
引用
- Ducassou S, Fernandes H, Savel H, et al. Prospective Evaluation of the First Option, Second-Line Therapy in Childhood Chronic Immune Thrombocytopenia: Splenectomy or Immunomodulation. J Pediatr. 2020. PMID: 33340549. doi:10.1016/j.jpeds.2020.12.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。